| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| PENPenumbra, Inc. | 12.27B | 313.43 | 870.64 | 12.86% | 12.3% | 12.07% | 1.2% | 0.19 |
| NUWENuwellis, Inc. | 1.72M | 1.90 | -0.24 | -1.4% | -202.83% | -423.93% | 0.08 | |
| NVNOenVVeno Medical Corporation | 7.3M | 0.36 | -0.28 | -74.59% | 0.03 | |||
| NSPRInspireMD, Inc. | 67.37M | 1.59 | -2.09 | 12.96% | -5.94% | -72.06% | 0.06 | |
| OMOutset Medical, Inc. | 99.48M | 5.48 | -2.23 | -12.8% | -73.12% | -61.67% | 7.53 | |
| SRDXSurmodics, Inc. | 614.51M | 42.98 | -52.41 | -4.91% | -14.59% | -15.84% | 0.28 | |
| AORTArtivion, Inc. | 2.01B | 42.50 | -132.81 | 9.75% | -2.16% | -2.08% | 0.55% | 1.31 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.01M | 15.08M | 49.94M | 102.6M | 115.38M | 130.38M | 113.69M |
| Revenue Growth % | - | 6.51% | 2.31% | 1.05% | 0.12% | 0.13% | -0.13% |
| Cost of Goods Sold | 8.12M | 32.88M | 62.97M | 94.99M | 97.54M | 101.38M | 75.13M |
| COGS % of Revenue | 4.05% | 2.18% | 1.26% | 0.93% | 0.85% | 0.78% | 0.66% |
| Gross Profit | -6.12M | -17.8M | -13.04M | 7.61M | 17.83M | 29M | 38.56M |
| Gross Margin % | -3.05% | -1.18% | -0.26% | 0.07% | 0.15% | 0.22% | 0.34% |
| Gross Profit Growth % | - | -1.91% | 0.27% | 1.58% | 1.34% | 0.63% | 0.33% |
| Operating Expenses | 40.45M | 52.51M | 104.43M | 138.13M | 178.85M | 198.77M | 151.94M |
| OpEx % of Revenue | 20.15% | 3.48% | 2.09% | 1.35% | 1.55% | 1.52% | 1.34% |
| Selling, General & Admin | 17.53M | 29.18M | 75.58M | 101.39M | 130M | 141.46M | 113.54M |
| SG&A % of Revenue | 8.74% | 1.94% | 1.51% | 0.99% | 1.13% | 1.09% | 1% |
| Research & Development | 22.92M | 23.33M | 28.85M | 36.74M | 48.85M | 57.31M | 38.4M |
| R&D % of Revenue | 11.42% | 1.55% | 0.58% | 0.36% | 0.42% | 0.44% | 0.34% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -46.56M | -70.31M | -117.47M | -130.52M | -161.02M | -169.77M | -113.38M |
| Operating Margin % | -23.2% | -4.66% | -2.35% | -1.27% | -1.4% | -1.3% | -1% |
| Operating Income Growth % | - | -0.51% | -0.67% | -0.11% | -0.23% | -0.05% | 0.33% |
| EBITDA | -45.07M | -68.37M | -113.71M | -124.33M | -154.74M | -163.96M | -107.65M |
| EBITDA Margin % | -22.46% | -4.53% | -2.28% | -1.21% | -1.34% | -1.26% | -0.95% |
| EBITDA Growth % | - | -0.52% | -0.66% | -0.09% | -0.24% | -0.06% | 0.34% |
| D&A (Non-Cash Add-back) | 1.49M | 1.94M | 3.75M | 6.18M | 6.28M | 5.81M | 5.73M |
| EBIT | -45.12M | -64.02M | -118.6M | -130.02M | -159.09M | -159.6M | -103.61M |
| Net Interest Income | -2.93M | -1.77M | -2.37M | -1.22M | -275K | -2.5M | -14.11M |
| Interest Income | 1.71M | 2.48M | 526K | 498K | 3.29M | 10.17M | 9.76M |
| Interest Expense | 4.64M | 4.26M | 2.89M | 1.72M | 3.57M | 12.68M | 23.87M |
| Other Income/Expense | -3.19M | 2.03M | -4.03M | -1.22M | -1.64M | -2.5M | -14.11M |
| Pretax Income | -49.76M | -68.28M | -121.49M | -131.74M | -162.66M | -172.27M | -127.48M |
| Pretax Margin % | -24.79% | -4.53% | -2.43% | -1.28% | -1.41% | -1.32% | -1.12% |
| Income Tax | 25K | 20K | 0 | 199K | 295K | 523K | 491K |
| Effective Tax Rate % | 1% | 1% | 0.99% | 1% | 1% | 1% | 1% |
| Net Income | -49.78M | -68.3M | -120.7M | -131.94M | -162.96M | -172.8M | -127.98M |
| Net Margin % | -24.8% | -4.53% | -2.42% | -1.29% | -1.41% | -1.33% | -1.13% |
| Net Income Growth % | - | -0.37% | -0.77% | -0.09% | -0.24% | -0.06% | 0.26% |
| Net Income (Continuing) | -49.78M | -68.3M | -121.49M | -131.94M | -162.96M | -172.8M | -127.98M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.65 | -34.06 | -2.83 | -2.89 | -3.38 | -3.48 | -2.46 |
| EPS Growth % | - | -19.64% | 0.92% | -0.02% | -0.17% | -0.03% | 0.29% |
| EPS (Basic) | -1.65 | -1.61 | -2.83 | -2.89 | -3.38 | -3.48 | -2.46 |
| Diluted Shares Outstanding | 2.01M | 2.01M | 2.85M | 3.04M | 3.21M | 3.31M | 3.46M |
| Basic Shares Outstanding | 2.01M | 2.01M | 2.85M | 3.04M | 3.21M | 3.31M | 3.46M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 147.65M | 79.65M | 345.91M | 409.8M | 373.64M | 291.22M | 258.22M |
| Cash & Short-Term Investments | 142.78M | 70.08M | 314.87M | 339.49M | 287.5M | 203.32M | 158.69M |
| Cash Only | 33.26M | 36.93M | 294.97M | 182.35M | 73.22M | 68.51M | 124.01M |
| Short-Term Investments | 109.52M | 33.15M | 19.9M | 157.14M | 214.28M | 134.81M | 34.67M |
| Accounts Receivable | 1.09M | 3.91M | 6.47M | 25.6M | 28.07M | 32.98M | 35.62M |
| Days Sales Outstanding | 197.87 | 94.75 | 47.28 | 91.07 | 88.8 | 92.33 | 114.36 |
| Inventory | 3.02M | 4.6M | 18.38M | 39.19M | 51.48M | 49.22M | 59.39M |
| Days Inventory Outstanding | 135.81 | 51.02 | 106.56 | 150.56 | 192.62 | 177.2 | 288.54 |
| Other Current Assets | 0 | 0 | 6.19M | 5.53M | 6.6M | 5.7M | 4.53M |
| Total Non-Current Assets | 3.48M | 8.72M | 57.92M | 53.66M | 26.47M | 22.58M | 17.57M |
| Property, Plant & Equipment | 2.93M | 7.89M | 23.25M | 20.2M | 21.99M | 18.65M | 12.07M |
| Fixed Asset Turnover | 0.69x | 1.91x | 2.15x | 5.08x | 5.25x | 6.99x | 9.42x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 151K | 743K | 0 | 33.31M | 3.31M | 0 | 0 |
| Other Non-Current Assets | 407K | 82K | 34.67M | 156K | 1.17M | 3.93M | 5.5M |
| Total Assets | 151.13M | 88.37M | 403.83M | 463.46M | 400.12M | 313.8M | 275.8M |
| Asset Turnover | 0.01x | 0.17x | 0.12x | 0.22x | 0.29x | 0.42x | 0.41x |
| Asset Growth % | - | -0.42% | 3.57% | 0.15% | -0.14% | -0.22% | -0.12% |
| Total Current Liabilities | 10.21M | 24.91M | 36.69M | 51.7M | 51.95M | 55.32M | 45.38M |
| Accounts Payable | 3.37M | 4.96M | 4.95M | 1.76M | 603K | 5.83M | 3.86M |
| Days Payables Outstanding | 151.58 | 55.06 | 28.68 | 6.77 | 2.26 | 20.98 | 18.76 |
| Short-Term Debt | 10K | 7.5M | 0 | 0 | 0 | 0 | 1.8M |
| Deferred Revenue (Current) | 269K | 883K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 2.23M | 4.61M | 10.82M | 17.49M | 19.85M | 24.77M | 26.96M |
| Current Ratio | 14.46x | 3.20x | 9.43x | 7.93x | 7.19x | 5.26x | 5.69x |
| Quick Ratio | 14.16x | 3.01x | 8.93x | 7.17x | 6.20x | 4.37x | 4.38x |
| Cash Conversion Cycle | 182.09 | 90.71 | 125.16 | 234.86 | 279.17 | 248.55 | 384.13 |
| Total Non-Current Liabilities | 428.87M | 435.64M | 38.53M | 37.69M | 102.18M | 135.59M | 203.6M |
| Long-Term Debt | 28.35M | 21.56M | 29.67M | 29.76M | 96.34M | 130.11M | 197.38M |
| Capital Lease Obligations | 9K | 0 | 8.04M | 6.89M | 5.58M | 4.48M | 2.68M |
| Deferred Tax Liabilities | -9K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 400.5M | 413.95M | 240K | 721K | 113K | 896K | 2.69M |
| Total Liabilities | 439.08M | 460.55M | 75.22M | 89.38M | 154.13M | 190.91M | 248.98M |
| Total Debt | 28.86M | 29.06M | 38.6M | 37.81M | 103.23M | 136.19M | 201.86M |
| Net Debt | -4.4M | -7.87M | -256.37M | -144.54M | 30.01M | 67.68M | 77.84M |
| Debt / Equity | - | - | 0.12x | 0.10x | 0.42x | 1.11x | 7.53x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -10.04x | -16.52x | -40.63x | -76.10x | -45.15x | -13.39x | -4.75x |
| Total Equity | -287.95M | -372.19M | 328.61M | 374.08M | 245.99M | 122.89M | 26.82M |
| Equity Growth % | - | -0.29% | 1.88% | 0.14% | -0.34% | -0.5% | -0.78% |
| Book Value per Share | -143.58 | -185.58 | 115.38 | 123.08 | 76.61 | 37.17 | 7.74 |
| Total Shareholders' Equity | -287.95M | -372.19M | 328.61M | 374.08M | 245.99M | 122.89M | 26.82M |
| Common Stock | 1K | 1K | 43K | 47K | 48K | 50K | 53K |
| Retained Earnings | -287.89M | -372.57M | -494.06M | -625.99M | -788.95M | -961.75M | -1.09B |
| Treasury Stock | 0 | -356K | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -60K | 22K | 1K | -184K | -564K | 68K | 42K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -46.44M | -70.29M | -99.02M | -130.26M | -145.73M | -131.37M | -116.3M |
| Operating CF Margin % | -23.14% | -4.66% | -1.98% | -1.27% | -1.26% | -1.01% | -1.02% |
| Operating CF Growth % | - | -0.51% | -0.41% | -0.32% | -0.12% | 0.1% | 0.11% |
| Net Income | -49.78M | -68.3M | -121.49M | -131.94M | -162.96M | -172.8M | -127.98M |
| Depreciation & Amortization | 1.07M | 1.94M | 3.16M | 5.16M | 5.17M | 5.81M | 5.73M |
| Stock-Based Compensation | 788K | 883K | 21.44M | 17.45M | 27.2M | 38.63M | 29.36M |
| Deferred Taxes | -75K | -4.11M | 2.49M | 3.08M | 0 | 0 | 0 |
| Other Non-Cash Items | 1.77M | 893K | 1.24M | 1.59M | 6M | -2.25M | 2.28M |
| Working Capital Changes | -217K | -1.6M | -5.85M | -25.6M | -21.14M | -773K | -25.69M |
| Change in Receivables | -552K | -2.89M | -2.57M | -19.14M | -2.51M | -5.09M | 0 |
| Change in Inventory | -2.21M | -5.02M | -16.29M | -22.04M | -14.73M | 1.65M | 0 |
| Change in Payables | 2.67M | 802K | 737K | -3.07M | -1.28M | 5.31M | -1.95M |
| Cash from Investing | -68.78M | 74.3M | 3.95M | -142.51M | -66.3M | 83.03M | 103.94M |
| Capital Expenditures | -1.77M | -3.29M | -9.11M | -3.11M | -8.32M | -3.44M | -912K |
| CapEx % of Revenue | 0.88% | 0.22% | 0.18% | 0.03% | 0.07% | 0.03% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -67.01M | 77.59M | 13.02M | -139.4M | -57.97M | 0 | 0 |
| Cash from Financing | 134.87M | 249K | 385.68M | 160.15M | 72.9M | 43.65M | 67.87M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 314K | 258K | 387.05M | 11.06M | 8.04M | 10.43M | 1.35M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -48.21M | -73.58M | -108.12M | -133.37M | -154.05M | -134.81M | -117.22M |
| FCF Margin % | -24.02% | -4.88% | -2.17% | -1.3% | -1.34% | -1.03% | -1.03% |
| FCF Growth % | - | -0.53% | -0.47% | -0.23% | -0.16% | 0.12% | 0.13% |
| FCF per Share | -24.04 | -36.69 | -37.96 | -43.88 | -47.98 | -40.78 | -33.84 |
| FCF Conversion (FCF/Net Income) | 0.93x | 1.03x | 0.82x | 0.99x | 0.89x | 0.76x | 0.91x |
| Interest Paid | 3.29M | 3.35M | 3.27M | 1.15M | 3.19M | 10.85M | 0 |
| Taxes Paid | 9K | 35K | 19K | 83K | 385K | 491K | 593K |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -36.73% | -37.55% | -52.56% | -93.69% | -170.97% |
| Return on Invested Capital (ROIC) | - | - | - | -64.88% | -47.78% | -54.58% | -57.6% |
| Gross Margin | -304.68% | -118.07% | -26.11% | 7.42% | 15.46% | 22.24% | 33.92% |
| Net Margin | -2480.32% | -452.97% | -241.71% | -128.59% | -141.24% | -132.54% | -112.57% |
| Debt / Equity | - | - | 0.12x | 0.10x | 0.42x | 1.11x | 7.53x |
| Interest Coverage | -10.04x | -16.52x | -40.63x | -76.10x | -45.15x | -13.39x | -4.75x |
| FCF Conversion | 0.93x | 1.03x | 0.82x | 0.99x | 0.89x | 0.76x | 0.91x |
| Revenue Growth | - | 651.27% | 231.18% | 105.47% | 12.45% | 13% | -12.8% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Product | 39.61M | 84.31M | 93.39M | 103.54M | 80.98M |
| Product Growth | - | 112.84% | 10.76% | 10.87% | -21.79% |
| Consumables Product | 6.74M | 19.18M | 28.8M | 42.21M | 51.15M |
| Consumables Product Growth | - | 184.47% | 50.15% | 46.56% | 21.18% |
| Service And Other Revenue | 10.32M | 18.29M | 21.99M | 26.84M | 32.71M |
| Service And Other Revenue Growth | - | 77.18% | 20.21% | 22.07% | 21.88% |
| Consoles Product | - | 65.13M | 64.59M | 61.33M | 29.83M |
| Consoles Product Growth | - | - | -0.83% | -5.05% | -51.36% |
Outset Medical, Inc. (OM) reported $120.1M in revenue for fiscal year 2024. This represents a 5883% increase from $2.0M in 2018.
Outset Medical, Inc. (OM) saw revenue decline by 12.8% over the past year.
Outset Medical, Inc. (OM) reported a net loss of $87.8M for fiscal year 2024.
Outset Medical, Inc. (OM) has a return on equity (ROE) of -171.0%. Negative ROE indicates the company is unprofitable.
Outset Medical, Inc. (OM) had negative free cash flow of $53.9M in fiscal year 2024, likely due to heavy capital investments.